Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TomoTherapy and Alliance Oncology to develop "first mobile radiation therapy"

This article was originally published in Clinica

Executive Summary

Radiation therapy company TomoTherapy has teamed up with Anaheim, California-based diagnostic service provider Alliance Oncology to develop what it calls the "world's first mobile radiation therapy service". The technology will be based on TomoTherapy's Hi-Art treatment system, which integrates CT imaging with radiation therapy to deliver precise treatment and minimise radiation to healthy tissue. The mobile trailers will be available to customers during construction of new systems, before system installation, to ease temporary backlogs, or as permanent systems in centres unable to expand their facilities. Madison, Wisconsin-based TomoTherapy said if successful, it would allow centres to upgrade ageing linear accelerators with no interruption in patient care. Financial details of the deal were not revealed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT040918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel